VIVUS Inc. (VVUS) Jumps 5.15% on February 15

Equities Staff  |

VIVUS Inc. (VVUS) was among the biggest gainers on the Russell 2000 for Monday February 15 as the stock popped 5.15% to $1.02, representing a gain of $0.05 per share. Some 1.42 million shares traded hands on 4,678 trades, compared with an average daily volume of 1.65 million shares out of a total float of 104.04 million. The stock opened at $0.98 and traded with an intraday range of $1.07 to $0.96.

After today's gains, VIVUS Inc. reached a market cap of $106.12 million. VIVUS Inc. has had a trading range between $3.14 and $0.92 over the last year, and it had a 50-day SMA of $1.02 and a 200-day SMA of $1.62.

Vivus is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. Its product line includes Qsymia for sleep apnea, STENDRA for erectile dysfunction.

VIVUS Inc. is based out of Mountain View, CA and has some 94 employees. Its CEO is Seth H.Z. Fischer.

For a complete fundamental analysis analysis of VIVUS Inc., check out’s Stock Valuation Analysis report for VVUS. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Dr Oliver Krause Founder Untitled Inc Part 1

Matt Bird sits down with Dr Oliver Krause, Founder Untitled Inc, in part 1 of this 2 part interview at the World Economic Forum at Davos 2019

Emerging Growth

Q BioMed Inc

Q BioMed Inc is a biomedical acceleration and development company. The company is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences…